FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		00540
Washington.	D.C.	20549

STATEMENT (OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
ONID APPROVAL									
OMB Number:	3235-0287								
Estimated average bur	den								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Gline Matthew					2. Issuer Name and Ticker or Trading Symbol Roivant Sciences Ltd. [ROIV]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Gille Matthew													X Director		10% Owner		ner	
(Last)	(Fir	st) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/29/2023								X Officer (below)	give title		Other (s below)	pecify
C/O ROIVANT SCIENCES LTD.					"	00/23/2023							CEO					
7TH FLOOR, 50 BROADWAY					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X Form filed by One Reporting Person				
LONDON				L									Form filed by More than One Reporting Person					
(City) (State) (Zip)					- R	Rule 10b5-1(c) Transaction Indication												
					_						.0b5-1(c). See			,,	Time pice	· tilat io	toriada to o	anoly the
		Ta	ble I - No	n-Dei	rivativ	ve Se	ecur	ities Acc	uired	Dis	posed of	f, or Ben	eficially	/ Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month/I				action 2A. Deemed Execution Date, if any (Month/Day/Year)				es Acquired (A) or Of (D) (Instr. 3, 4 and 5)) Securitie: Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		Direct Indirect It. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)				
								Code	v	Amount	ount (A) or (D)		Transacti (Instr. 3 a	on(s)			msu. 4)	
Common Shares 08/27					27/202	7/2023		M ⁽¹⁾		12,088	A	(1)	1,05	1,051,732		D		
Common Shares 08/28					28/202	8/2023			J ⁽²⁾ 6,78		6,784	D	\$11.25	1,04	.,948 Г		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Scurity (Instr. 3) 2. Conversion Date (Month/Day/Year Price of Derivative Security			3A. Deemed Execution D if any (Month/Day/	Date, Trans Code		sunsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)					9. Numb derivativ Securitie Benefici Owned Followin Reported Transact	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount of Number of Shares		(Instr. 4)		<u></u>	
Capped Value Appreciation	(1)(4)	05/27/2023			M			28,410 ⁽¹⁾	(1)		03/31/2026	Common Shares	12,088	\$6.4(1)	1,193,2	47 ⁽⁴⁾	D	

Explanation of Responses:

- 1. Reflects the conversion of 28,410 capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at \$12.68 per share) as of the relevant date of determination over (B) the hurdle price of \$6.40 per share (such excess, the "CVAR Amount"). On August 27, 2023, the "knock-in" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023.
- 2. Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's "sell to cover" policy and does not represent a discretionary sale by the reporting person.
- 3. The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.08 to \$11.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- 4. This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than \$9.20 per share as of the relevant date of determination (the "knock-in condition"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs.

By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline

08/29/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.